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TO THE EDITOR
Dermatofibrosarcoma protuberans
(DFSP) is a dermal tumor of interme-
diate malignancy. Propensity for meta-
stases is low but local recurrence risk is
high unless a wide surgical excision is
performed. In addition to the classical
presentation of DFSP, several clinical
and histological variants have been
described, such as DFSP-containing
fibrosarcomatous areas or malignant
fibrous histiocytoma areas, Bednar
tumor, giant cell fibroblastoma, and
superficial adult fibrosarcoma (Simon
et al., 1997; Sheng et al., 2001; Maire
et al., 2002a; Sirvent et al., 2003;
Bianchini et al., 2007; Szollosi et al.,
2007). DFSP and related tumors are
molecularly characterized by the
presence of an abnormal chimeric
gene that fuses COL1A1 (17q21.3)
with platelet-derived growth factor-B
chain (PDGFB) (22q13.1) (Simon
et al., 1997). The detection of COL1A1–
PDGFB is mandatory in case of unusual
clinical or histological presentation, as
well as in pediatric cases (Sirvent et al.,
2003; Bianchini et al., 2007; Maire
et al., 2007). A striking feature of
COL1A1–PDGFB fusion consists of the
high variability of the break point
location between the exons 6 and 49
of COL1A1 (Sirvent et al., 2003; Bian-
chini et al., 2007). In contrast, the break
point in PDGFB is consistently located
in the first intron. We have investigated
whether the COL1A1 break point loca-
tion is associated with clinical or
histological features. In such a case,
the precise detection of the COL1A1
break point detection by using multi-
plex reverse transcriptase–PCR and se-
quencing could be useful for diagnosis
or evaluation of prognosis. For this
purpose we compiled a series of 172
DFSP cases with both molecular and
clinico-histological data (Supplemen-
tary Table S1), including (i) 35 cases of
DFSP or related tumors addressed for
molecular diagnosis referral to the
laboratory of Solid Tumors Genetics
(Nice, France) from nine different
French Hospitals and previously unre-
ported; (ii) 22 DFSP cases previously
published by our group (Pedeutour
et al., 1994, 1995, 1996; Simon et al.,
1997; Greco et al., 1998; Navarro et al.,
1998; Maire et al., 2002a, b, c, 2007;
Terrier-Lacombe et al., 2003; Jouary
et al., 2007); (iii) 115 cases published
between 1997 and 2008 (O’Brien et al.,
1998; Wang et al., 1999, 2000; Vanni
et al., 2000; Sheng et al., 2001; Gokden
et al., 2003; Sandberg et al., 2003;
Sirvent et al., 2003; Saeki et al.,
2003a, b, 2005, 2006; Martin et al.,
2005; Craver et al., 2006; Kashima
et al., 2006; Llombart et al., 2006,
2008; Nakanishi et al., 2007; Szollosi
et al., 2007; Takahira et al., 2007;
Patel et al., 2008). The description of
the clinical and histological features of
the 172 cases is compiled in Supple-
mentary Table S1.
Continuous data (age, tumor size)
were described with mean, SD, and range
(minimum–maximum); nominal scale
data (gender, anatomic location, histolo-
gical variant) were described by frequen-
cies and relative frequencies (expressed
as percentage). A Fisher exact test showed
no significant differences in terms of
gender, clinical presentation, and histo-
logical variant between our series and
tumors studied by other groups (Table 1).
Similarly, an unpaired Student’s t-test
showed no significant differences in the
two series in terms of tumor size. In
contrast, a slight difference between the
two series was observed for the anatomic
location and the mean age. The first could
be explained by reports of exceptional
anatomical locations in the literature, and
the later by a more frequent recruitment
of pediatric patients in our laboratory.
The very high variability of the
COL1A1 break point position was
confirmed, as 38 different COL1A1
exons have been identified. The most
frequently rearranged COL1A1 exons
were exon 25 (n¼ 19), 32 (n¼18), and
47 (n¼ 15) (Figure 1).
A standard analysis of variance of
the COL1A1 break point position with
respect to the clinico-histological para-
meters was performed by grouping the
break points into four distinct groups of
11 exons each (group A: exons 6–16;
group B: exons 17–27; group C: exons
28–38; and group D: exons 39–49). The
following parameters were tested for
the COL1A1 break point position: age,
histological variant, anatomic location,
and gender. None of the parameters
tested showed a significant association
with the either group. Only the ana-
tomic location showed a slight trend,
P¼0.01843 (Supplementary Table S2).
Also, no significant correlation between
the most represented COL1A1 break
points (n45) (exons 7, 25, 29, 32,
33–34, 40, 42, 46, and 47) and clinical
or histological features was observed.
This result is consistent with the role of
the COL1A1 side of the fusion gene as
a simple cis element for PDGFB over-
expression (Greco et al., 1998; Simon
et al., 2001). The spectacular clinical
effect of tyrosine kinase receptor inhi-
bitor (imatinib mesylate) also supports
the major role of the PDGFR activation
through the overexpression of PDGFB
Abbreviations: COL1A1, collagen type I-a 1; DFSP, dermatofibrosarcoma protuberans; PDGFB, platelet-
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in the DFSP oncogenesis (Maki et al.,
2002; Rubin et al., 2002; Mizutani
et al., 2004; McArthur et al., 2005).
In conclusion, we have demons-
trated that although the COL1A1-
PDGFB fusion detection is necessary
for assessing the diagnosis of DFSP,
the determination of the COL1A1 break
point position within the fusion gene
does not provide any medically
valuable information. Therefore, inter-
phase fluorescence in situ hybridization
analysis (which is simpler to handle but
does not indicate the location of the
break point within COL1A1) seems to
be a more appropriate method than
multiplex reverse transcriptase–PCR for
routine detection of COL1A1–PDGFB.
The reverse transcriptase–PCR and se-
quencing analysis should be reserved
for validation of unexpected negative
fluorescence in situ hybridization results
and for research prospective purposes.
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Table 1. Comparison between our cases and the literature for main
clinico-pathological features
% From the literature (n) % From our series (n) Total % P-value
Sex 0.84
Female 48 (54) 52 (29) 49
Male 52 (59) 48 (28) 51
100 (113) 100 (57)
Anatomical location 0.038
Trunk 57 (64) 49 (28) 54
Lower limb 25 (28) 19 (11) 23
Upper limb 8 (9) 19 (11) 12
Head and neck 5 (6) 7 (4) 6
Genitalia 4 (5) 2 (1) 3
Lung 1 (1) 4 (2) 2
100 (113) 100 (57)
Clinical presentation 0.69
Nodular 74 (16) 72 (26) 71
Atrophic 13 (3) 20 (8) 19
Atrophic and nodular 13 (3) 7 (3) 10
100 (22) 100 (37)
Histological variant 0.93
DFSP 55 (63) 70 (37) 60
DFSP-FS 22 (25) 13 (7) 19
GCF 5 (6) 7 (8) 8
Myxoid DFSP 7 (8) 0 (0) 5
BT 5 (6) 2 (1) 4
SAF 3 (4) 0 (0) 2
DFSP-MFH 3 (3) 0 (0) 2
100 (115) 100 (53)
BT, Bednar tumor; DFSP, dermatofibrosarcoma protuberans; DFSP-FS, dermatofibrosarcoma
protuberans with fibrosarcoma component; DFSP-MFH, dermatofibrosarcoma protuberans with
malignant fibrous histiocytoma areas; GCF, giant cell fibroblastoma; SAF, superficial adult
fibrosarcoma.
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Figure 1. Position of the COL1A1 gene break points involved in the COL1A1–PDGFB fusion gene.
The white arrow represents the COL1A1 gene and each vertical arrowhead indicates a break point in
a single case. The numbers within indicate some COL1A1 exons number. Upper part: cases from our
group; black arrowheads: 35 previously unreported cases; white arrowheads: 22 previously published
cases (Pedeutour et al., 1994, 1995, 1996; Simon et al., 1997; Greco et al., 1998; Navarro et al., 1998;
Maire et al., 2002a, b, c, 2007; Terrier-Lacombe et al., 2003; Jouary et al., 2007). Lower part, gray
arrowheads: 115 cases retrieved from the literature (O’Brien et al., 1998; Wang et al., 1999, 2000; Vanni
et al., 2000; Sheng et al., 2001; Gokden et al., 2003; Sandberg et al., 2003; Sirvent et al., 2003; Saeki
et al., 2003a, b, 2005, 2006; Martin et al., 2005; Craver et al., 2006; Kashima et al., 2006; Llombart et al.,
2006, 2008; Nakanishi et al., 2007; Szollosi et al., 2007; Takahira et al., 2007; Patel et al., 2008).
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